Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is advancing its pipeline with the pivotal Phase 3 study of deucrictibant for treating and preventing hereditary angioedema (HAE) attacks, with a revised global peak sales estimate of $1.65 billion by 2037, reflecting increasing confidence in its market potential. The CHAPTER-1 study highlighted an impressive 84.5% reduction in HAE attack rates, along with consistent improvements in health-related quality of life for all patients assessed, which bolsters the drug’s therapeutic profile. The promising outcomes observed in both prophylactic and on-demand settings, coupled with a lack of approved therapies in this niche market, position deucrictibant favorably for market penetration upon approval.

Pharvaris NV faces a negative outlook due to several fundamental concerns regarding its market position and drug development strategy. Key issues include the uncertain efficacy of its bradykinin B2 receptor antagonist in the chronic prophylaxis setting and the highly competitive landscape of the hereditary angioedema (HAE) market, where established therapies dominate. Additionally, if Pharvaris fails to secure adequate funding for its pipeline advancement, this could further jeopardize its growth and successful market entry, particularly as multiple subcutaneous therapies are poised to enter the market within the next three years.